Inozyme Pharma (INZY) Projected to Post Quarterly Earnings on Tuesday

Inozyme Pharma (NASDAQ:INZY) is anticipated to release its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter.

Inozyme Pharma Price Performance

Shares of NASDAQ INZY opened at $0.96 on Tuesday. The firm has a 50-day simple moving average of $1.01 and a 200-day simple moving average of $2.20. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $61.96 million, a price-to-earnings ratio of -0.62 and a beta of 1.39. Inozyme Pharma has a 52 week low of $0.72 and a 52 week high of $6.24.

Analysts Set New Price Targets

INZY has been the subject of a number of analyst reports. Needham & Company LLC restated a “buy” rating and issued a $15.00 price target on shares of Inozyme Pharma in a research report on Tuesday, April 8th. Wedbush reiterated an “outperform” rating and set a $7.00 price target (down from $12.00) on shares of Inozyme Pharma in a report on Monday, March 10th. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Inozyme Pharma in a report on Thursday, April 10th. Raymond James lowered their price objective on shares of Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating for the company in a research note on Wednesday, March 12th. Finally, Wells Fargo & Company reduced their target price on shares of Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, January 13th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $14.63.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.